Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link
Dow Jones Industrial Average
) is trading up 88 points (+0.5%) at 17,089 as of Monday, Aug 25, 2014, 1:36 p.m. ET. During this time, 116.7 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 300.8 million. The NYSE advances/declines ratio sits at 1,800 issues advancing vs. 1,153 declining with 188 unchanged.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
The Dow component leading the way higher looks to be
), which is sporting a two-cent gain to $28.94. This single gain is lifting the Dow Jones Industrial Average by 0.15 points or roughly accounting for 0.2% of the Dow's overall gain. Volume for Pfizer currently sits at 11.6 million shares traded vs. an average daily trading volume of 23.7 million shares.
Pfizer has a market cap of $182.74 billion and is part of the health care sector and drugs industry. Shares are down 5.6% year-to-date as of Friday's close. The stock's dividend yield sits at 3.6%.
Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products.
TheStreet Ratings rates Pfizer as a
. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.
- You can view the full Pfizer Ratings Report.